LEADER 04184nam  22006615  450 
001 9910908379503321
005 20241115120007.0
010   $a9789819775682$b(electronic bk.)
010   $z9789819775675
024 7 $a10.1007/978-981-97-7568-2
035   $a(MiAaPQ)EBC31784475
035   $a(Au-PeEL)EBL31784475
035   $a(CKB)36590257200041
035   $a(DE-He213)978-981-97-7568-2
035   $a(EXLCZ)9936590257200041
100   $a20241115d2024      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aSodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure $eMechanisms and Clinical Applications: A Machine-Generated Literature Overview /$fedited by Mukesh Nandave
205   $a1st ed. 2024.
210  1$aSingapore :$cSpringer Nature Singapore :$cImprint: Springer,$d2024.
215   $a1 online resource (536 pages)
311 08$aPrint version: Nandave, Mukesh Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure Singapore : Springer,c2024 9789819775675 
327   $aChapter 1_ The History of the Development of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors for the Treatment of Diabetes: from biology to Chemistry -- Chapter 2_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors and mechanism of cardiovascular benefits in type 2 diabetes  -- Chapter 3_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for primary and secondary protection from cardiovascular and renal diseases in Type 2 diabetes -- Chapter 4_ Sodium-glucose Cotransporter-2 (SGLT2) inhibitors: Emerging opportunities for the treatment of myocardial infarction -- Chapter 5_ Potential Role of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy -- Chapter 6_ Contemporary Management, unmet needs, and Therapeutic Potential of Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in congestive heart failure -- Chapter 7 A comprehensive review of preclinical and clinical information on the cardiovascular advantages of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors -- Chapter 8_ Exploring the current selective drugs of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of cardiovascular disease in Type 2 Diabetes -- Chapter 9_ A comprehensive review of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor?s effects on cardiovascular events, mortality, and significant safety outcomes in individuals with type 2 diabetes.
330   $aThe auto-summaries have been generated by a recursive clustering algorithm via the Dimensions Auto-summarizer by Digital Science handled by Subject Matter Experts and the editor(s) of this book. The editor(s) of this book selected which SN content should be auto-summarized and decided its order of appearance. Please be aware that these are extractive auto-summaries, which consist of original sentences, but are not representative of its original paper, since we do not show the full length of the publication. Please note that only published SN content is represented here, and that machine-generated books are still at an experimental stage.
606   $aPharmacology
606   $aMedicine$xResearch
606   $aBiology$xResearch
606   $aPharmacovigilance
606   $aMedicine
606   $aCardiology
606   $aPharmacology
606   $aBiomedical Research
606   $aDrug Safety and Pharmacovigilance
606   $aClinical Medicine
606   $aCardiology
615  0$aPharmacology.
615  0$aMedicine$xResearch.
615  0$aBiology$xResearch.
615  0$aPharmacovigilance.
615  0$aMedicine.
615  0$aCardiology.
615 14$aPharmacology.
615 24$aBiomedical Research.
615 24$aDrug Safety and Pharmacovigilance.
615 24$aClinical Medicine.
615 24$aCardiology.
676   $a615
700   $aNandave$b Mukesh$01737180
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
912   $a9910908379503321
996   $aSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure$94291093
997   $aUNINA